Samsung Bioepis Flags Biosimilar Market Shifts in Q2 2026 Report
Event summary
- Samsung Bioepis released its Q2 2026 US Biosimilar Market Report, tracking 92 approved biosimilars across 20 molecules (73% launched).
- Adalimumab biosimilar adoption hit 60%, including private-label sales data for the first time.
- Ustekinumab biosimilars saw a 73% ASP price drop due to Medicare Part B recalibration.
- Denosumab and ustekinumab biosimilars show wide pricing variance (6–86% discounts vs. reference products).
The big picture
Samsung Bioepis’ report underscores the US biosimilar market’s rapid evolution, driven by FDA guidance easing comparative efficacy requirements and payer demand for cost transparency. The 73% ASP drop in ustekinumab highlights how Medicare reimbursement adjustments can upend pricing dynamics, while adalimumab adoption nearing 60% reflects maturing competition in blockbuster categories.
What we're watching
- Regulatory Flexibility
- How FDA’s shift toward analytical evidence will accelerate biosimilar approvals.
- Pricing Volatility
- Whether ustekinumab ASP corrections signal broader Medicare Part B recalibrations.
- Private-Label Impact
- The pace at which Quallent and Cordavis private-label biosimilars disrupt market share.
Related topics